Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ironwood Pharma ( (IRWD) ) has shared an update.
On June 10, 2025, Ironwood Pharmaceuticals held its Annual Meeting of Stockholders, where nine directors were elected to serve a one-year term on the board. Additionally, stockholders approved executive compensation and ratified Ernst & Young LLP as the independent public accounting firm for 2025.
The most recent analyst rating on (IRWD) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
Ironwood Pharma’s overall stock score is hindered by financial challenges, notably a negative equity position and declining revenues. The technical analysis reflects a bearish trend, compounded by valuation concerns due to a negative P/E ratio. Moreover, the potential delisting risk following the Nasdaq deficiency letter further dampens investor sentiment. Positive cash flow remains a key strength, although overshadowed by broader financial and operational risks.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Ironwood Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative medicines.
Average Trading Volume: 3,448,254
Technical Sentiment Signal: Sell
Current Market Cap: $129.3M
For a thorough assessment of IRWD stock, go to TipRanks’ Stock Analysis page.